Navigation Links
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Date:2/6/2008

Data also showed differences in gastrointestinal and lipid effects between

REYATAZ/ritonavir and lopinavir/ritonavir among study population

PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced results from the CASTLE study, in which 300 mg of once-daily REYATAZ(R) (atazanavir sulfate) taken with 100 mg of ritonavir (REYATAZ/r) showed similar antiviral efficacy to twice-daily lopinavir 400 mg and ritonavir 100 mg (lopinavir/r) in previously untreated adult HIV-1 infected patients at 48 weeks, as part of HIV combination therapy. In this study, 78 percent of the 440 patients in the REYATAZ/r arm met the primary endpoint of achieving undetectable viral load (defined as HIV-1 RNA less than 50 copies/mL) at 48 weeks, compared with 76 percent of the 443 patients in the lopinavir/r arm.

CASTLE is the first large-scale, open-label, randomized study designed to demonstrate the non-inferiority of REYATAZ/r to lopinavir/r in previously untreated HIV-1 infected adult patients. Data from the CASTLE study were presented for the first time at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) this week in Boston, Mass.

"The CASTLE study provides important additional data to inform the use of a once-daily regimen including REYATAZ and ritonavir in antiretroviral-naive HIV-infected patients," said Jean-Michel Molina, M.D., Hopital Saint Louis, Paris, France. "When choosing a treatment in previously untreated patients it is important to ensure antiviral activity as well as tolerability to optimize the management of HIV infection over the long term."

The most common grade 2-4 adverse events occurring in greater than or equal to three percent of patients
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
2. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
3. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Inverseon Announces Positive Phase IIa Asthma Study
6. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
7. Study Says Allergy Shots Help Children, Reduce Health Care Costs
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
10. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
11. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)...  The fairness of the proposed acquisition of Thoratec ... ("St. Jude") is the subject of an investigation by ... firm.  The investigation is focusing on possible breaches of ... Board of Directors of THOR for agreeing to sell ... Company announced it had reached a definitive agreement for ...
(Date:7/27/2015)... BOULDER, Colo. , July 27, 2015 ... will report financial results for the fourth ... and hold a conference call to discuss ... Ron Squarer, Chief Executive Officer will lead ... 2015Time:9:00 a.m. Eastern TimeToll-Free:(844) 464-3927Toll:(765) 507-2598Pass Code: ...
(Date:7/27/2015)... As per the new market report ... Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2021," ... 2014, growing at a CAGR of 13.2% from 2015 to ... The global bionics market is growing primarily due to ... to paralysis or amputation of body parts. In addition, increasing ...
Breaking Medicine Technology:WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4
... SCHAUMBURG, Ill., Sept. 30 Sagent Pharmaceuticals, Inc., ... that it has launched vinorelbine injection, USP, an ... of vinorelbine injection, USP in the United States ... shipping vinorelbine injection immediately. , "Sagent has launched ...
... ROCKLAND, Mass., Sept. 30 EMD Serono, ... today the submission of a New Drug Application (NDA) ... Cladribine Tablets, EMD Serono,s proprietary investigational oral formulation of ... with relapsing forms of multiple sclerosis (MS). Cladribine Tablets ...
Cached Medicine Technology:Sagent Pharmaceuticals Launches Vinorelbine Injection, USP 2EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 2EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 3EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 4
(Date:7/27/2015)... Lexington, Kentucky (PRWEB) , ... July 28, 2015 ... ... KORT (Kentucky Orthopedic Rehab Team) as the sports medicine provider for the entire ... (ACHS). , According to ACHS Athletic Director Rick Sallee, “Student safety and ...
(Date:7/27/2015)... ... July 28, 2015 , ... The National Association ... 2015 Professional Woman of the Year. Ms. Baum-Lappe is recognized with this prestigious ... women in the country, spanning virtually every industry and profession, the National Association ...
(Date:7/27/2015)... ... 27, 2015 , ... In a piece published July 22 on ... surgery and explained why people should not shy away from their own personal aspirations. ... the few and celebrate it for the modern wonder that it is.” This is ...
(Date:7/27/2015)... ... ... The Maricopa Community Colleges today announced a new program that ... into and complete college. , The “Bridging Success Initiative,” funded by the ... from across the valley. , The initiative advisory board has representatives from Arizona State ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ... hiking to its options. Already an industry leader because of its use ... lookout for the latest successful trends in helping people to overcome addiction and ...
Breaking Medicine News(10 mins):Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 2Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 3Health News:NAPW Inducts Gilda Baum-Lappe, Journalist / Correspondent of Hollywood Foreign Press Association Into its VIP Woman of the Year Circle 2Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... new class of drugs based on a widely used ... the laboratory and in mice, according to researchers. The ... treatment of these tumors. // ,Previous drugs ... same cell targets as hydroxyurea, but had serious side ...
... mantra of the media as dozens of people exposed to ... potent antibiotic. But if the supply dwindles, doctors say other ... previous generation's wonder drug: penicillin. Although alternatives exist, Cipro is ... , // ,It helped that Cipro was the ...
... An experimental anti-cancer drug has shown effectiveness in treating ... report. Researchers say the drug probably acts on many ... for treating other types of cancer. Dr. Antonio Fojo ... colleagues tested the drug, depsipeptide//, in patients with T-cell ...
... virus that kills at least 30 percent of its ... the globe more than two decades ago. Scientists retained ... and stored them in secure laboratories in Atlanta, Georgia, ... of many potential bioterrorism threats, but "perhaps it is ...
... warned doctors that doxycycline -- an antibiotic being prescribed ... -- can stunt fetal growth when taken by pregnant ... urged doctors to prescribe Cipro to pregnant women. The ... being overprescribed in the general population, possibly causing common ...
... drugs, statements about drug benefits are often overblown ... expected benefit; instead, they make an emotional appeal," ... New Hampshire. // ,Instead of telling ... medicine is going to prevent some outcome, these ...
Cached Medicine News:
... EXPRESS Seeding Cartridge System is a single-use, ... seeds and spacers into a Bard BrachyStar ... has a(n): outer radiation safety shield, inner ... spacers, integrally molded fitting that connects the ...
... Luna is a very easy to use ... in close co-operation with practising urologists as ... lower urinary tract dysfunctions. The system offers ... and flow during a natural bladder filling, ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... Dorado™ will exceed your expectations with ... flexible enough to be customized to meet ... your needs grow, Dorado™ can be upgraded ... such as video and database management, it ...
Medicine Products: